Baird Financial Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

Baird Financial Group’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-47,250	Closed	-$227K	–	1592
2019 Q4	$227K	Hold	47,250	–	–	﹤0.01%	1431
2019 Q3	$286K	Hold	47,250	–	–	﹤0.01%	1332
2019 Q2	$307K	Hold	47,250	–	–	﹤0.01%	1325
2019 Q1	$335K	Hold	47,250	–	–	﹤0.01%	1126
2018 Q4	$230K	Hold	47,250	–	–	﹤0.01%	1182
2018 Q3	$331K	Buy	47,250 +850	+2%	+$6.24K	﹤0.01%	1154
2018 Q2	$296K	Hold	46,400	–	–	﹤0.01%	1142
2018 Q1	$252K	Hold	46,400	–	–	﹤0.01%	1160
2017 Q4	$193K	Hold	46,400	–	–	﹤0.01%	1220
2017 Q3	$447K	Hold	46,400	–	–	﹤0.01%	1016
2017 Q2	$549K	Hold	46,400	–	–	﹤0.01%	937
2017 Q1	$595K	Hold	46,400	–	–	﹤0.01%	906
2016 Q4	$568K	Buy	+46,400	New	+$551K	﹤0.01%	893

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baird Financial Group's GNMK Position: Q1 2020 in Review

Baird Financial Group sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2020, closing a stake of 47,250 shares — an estimated $227K sold.

Baird Financial Group first reported a position in GNMK in Q4 2016 and held it in 13 quarters. The position peaked at $595K in Q1 2017. 110 funds tracked by Wall St. Rank hold GNMK as of Q1 2020.

Baird Financial Group reported no remaining GenMark Diagnostics, Inc position as of Q1 2020 after selling out during the quarter.
Baird Financial Group sold 47,250 GenMark Diagnostics, Inc shares in Q1 2020, an estimated $227K.
Baird Financial Group first reported a position in GenMark Diagnostics, Inc in Q4 2016 and held it in 13 quarters.
Baird Financial Group's GenMark Diagnostics, Inc position peaked at $595K in Q1 2017.
110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2020.

Based on Baird Financial Group's 13F filing for Q1 2020, filed 14 May 2020.